The role of lymphadenectomy in esophageal cancer

Darling, Gail

doi:10.1002/jso.21209

Cited by 42 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However these differences were not large enough to show significance, presumably because of the relatively small number of patients recruited. Furthermore, as several studies have reported correlations between dissected lymph node numbers and long-term survival (21,22), we recommend that a larger scale comparative study should be conducted on RE and TE.…”

Section: Figurementioning

confidence: 99%

Comparison of robot-assisted esophagectomy and thoracoscopic esophagectomy in esophageal squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

Background: The aim of the study was to compare robot-assisted esophagectomy (RE) with thoracoscopic esophagectomy (TE) for the treatment of esophageal squamous cell carcinoma (ESCC).Methods: A total of 105 patients who underwent RE (n=62) or TE (n=43) due to ESCC were included in this study. Early postoperative outcomes and long-term survivals between the two groups were compared.Results: The RE and TE groups were comparable in preoperative clinical characteristics. Total operation times were not significantly different between the two groups (490 minutes in RE vs. 458 minutes in TE; P=0.118). The total number of dissected lymph nodes was significantly greater in the RE group (37.3±17.1 vs. 28.7±11.8; P=0.003), and intergroup differences were significant for numbers of lymph nodes dissected from the upper mediastinum (10.7±9.7 in RE vs. 6.3±9.3 in TE; P=0.032) and the abdomen (12.2±8.7 in RE vs. 7.8±7.1 in TE; P=0.007). Five-year overall survival was not different between the two groups (69% in RE and 59% in TE; P=0.737).Conclusions: Better quality lymphadenectomy could be achieved in RE although survival benefit was not clear. Prospective randomized studies comparing the RE and TE are necessary.

show abstract

Section: Figurementioning

confidence: 99%

Comparison of robot-assisted esophagectomy and thoracoscopic esophagectomy in esophageal squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…These micrometastatic deposits can be detected with immunohistochemical analysis using monoclonal antibodies to stain tumour-specific antigens or using Polymerase Chain reaction (PCR) at the molecular level [37][38][39][40][41][42][43][44]. It is unclear whether these nodal micrometastases represent tumour cells with metastatic potential or just shredded cells, which will be cleared by the immune system or remain dormant in a non-proliferating phase [39,45].…”

Section: Micrometastases In Lymph Nodesmentioning

confidence: 99%

“…Studies have demonstrated that distant lymph node metastases occur in up to 40% of patients, with T2 and T3 tumours having a prevalence of 31% and 40% positive distant lymph nodes, respectively [11,42,59]. Distant lymph node metastases to upper mediastinum lymph nodes occur almost exclusively in patients with extensive regional lymph node involvement [96,100].…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Lymph node metastases and prognosis in oesophageal carcinoma – A systematic review

Kayani

Zacharakis

Ahmed

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Oesophageal cancer is the seventh most common cause of cancer-related death in the developed world and the incidence of oesophageal adenocarcinoma is now the fastest growing of any gastrointestinal cancer. Lymph node involvement is the single most important prognostic factor in oesophageal cancer. Imaging to determine the extent of lymph node involvement and plan treatment often requires a combination of modalities to avoid under-staging. The seventh edition of the staging system released by the International Union Against Cancer (IUCC) has stratified lymph node involvement according to the number of lymph nodes involved and redefined its groupings for location of metastatic lymph node involvement. This review discusses the prognostic and treatment implications of these modifications and explores micrometastatic lymph node involvement, capsular infiltration and lymph node ratio as possible additions to the staging system.

show abstract

“…Epidemiological studies indicate that ESCC is the fifth most common cause of cancer-related mortality in men (1). Despite significant improvements in diagnosis and treatment including surgery, chemotherapy and radiotherapy, patient prognosis remains poor, with a 5-year survival rate of 15-34% (2)(3)(4). Systemic chemotherapy with cisplatin and 5-fluorouracil (5-FU) is the most commonly used treatment regimen for advanced ESCC.…”

Section: Introductionmentioning

confidence: 99%

Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma

et al. 2014

View full text Add to dashboard Cite

Abstract.A malignant esophageal cancer, squamous cell carcinoma is one of the most prevalent cancers. Despite the use of present surgical techniques combined with various treatment modalities, the overall 5-year survival rate remains at 15-34%. Epidermal growth factor receptor (EGFR) is the most well studied receptor in various cancers and EGFR overexpression is detected in 40% of esophageal squamous cell carcinomas (ESCCs) and ESCC cell lines. To examine the EGFR antibody combination effect, we used treatment with cisplatin and cetuximab in ESCC cell lines, TE-4 and TE-8. Combination of cetuximab and cisplatin resulted in a growth inhibition only in the EGFR overexpressed TE-8 cell line. Furthermore, we confirmed that cisplatin-induced EGFR activation was inhibited by cetuximab in TE-8 but not in TE-4 cells. Our data suggest that cetuximab combined with cisplatin exerts antitumorigenic effects in vitro and in vivo via suppression of EGF signaling, which can be applied toward targeted ESCC treatments.

show abstract

The role of lymphadenectomy in esophageal cancer

Cited by 42 publications

References 29 publications

Comparison of robot-assisted esophagectomy and thoracoscopic esophagectomy in esophageal squamous cell carcinoma

Comparison of robot-assisted esophagectomy and thoracoscopic esophagectomy in esophageal squamous cell carcinoma

Lymph node metastases and prognosis in oesophageal carcinoma – A systematic review

Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma

Contact Info

Product

Resources

About